Core Viewpoint - 加科思-B (01167) has seen a significant increase in stock price, rising over 11% and reaching 8.69 HKD, with a trading volume of 73.82 million HKD, following the announcement of a capital increase and equity transfer agreement with Haisheng Capital [1] Group 1 - 加科思 has received a first payment of 125 million RMB from Haisheng Capital, which enhances the company's cash reserves and supports the development of its innovative oncology therapy pipeline [1] - The agreement involves Haisheng Capital acquiring 80% of the equity in Beijing Jakesi's subsidiary, Jakesi Ruikang, with a total payment structure including a milestone payment of 75 million RMB [1] - Following the completion of this transaction, 加科思's ownership in Jakesi Ruikang will decrease to 10%, aligning with the company's strategic focus on key pipeline products targeting different critical cellular pathways in oncology [1]
港股异动 | 加科思-B(01167)再涨超11% 近期收到海松资本1.25亿元首付款 公司此...